新型免疫抑制剂FK506对MRL/MpJ-lpr/lpr小鼠自发性狼疮性肾炎的影响。
Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
作者信息
Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S
机构信息
Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
出版信息
Nephron. 1993;64(3):471-5. doi: 10.1159/000187375.
We evaluated the effect of the novel immunosuppressive agent, FK506, which is known to inhibit T cell immunity, on the development of lupus nephritis in MRL/MpJ-lpr/lpr (MRL/l) mice. FK506 was administered subcutaneously (1 mg/kg body weight) from 12 to 20 weeks of age in 13 MRL/l mice with spontaneous lupus nephritis. Nine animals receiving no treatment were used as the control. FK506 significantly reduced the development of proteinuria, lowered the level of BUN, and suppressed the elevation of serum anti-dsDNA antibodies. Histopathological study showed that FK506 significantly inhibited the progression of glomerular hypercellularity and crescent formation. Glomerular deposition of C3 was significantly reduced in the FK506-treated mice compared to the nontreated controls. These findings suggest that FK506 may protect against progression of lupus nephritis in MRL/l mice, an animal model of systemic lupus erythematosus.
我们评估了新型免疫抑制剂FK506（已知其可抑制T细胞免疫）对MRL/MpJ-lpr/lpr（MRL/l）小鼠狼疮性肾炎发展的影响。13只患有自发性狼疮性肾炎的MRL/l小鼠在12至20周龄时皮下注射FK506（1毫克/千克体重）。9只未接受治疗的动物用作对照。FK506显著减少了蛋白尿的发展，降低了血尿素氮水平，并抑制了血清抗双链DNA抗体的升高。组织病理学研究表明，FK506显著抑制了肾小球细胞增多和新月体形成的进展。与未治疗的对照组相比，FK506治疗的小鼠中C3的肾小球沉积显著减少。这些发现表明，FK506可能预防MRL/l小鼠（系统性红斑狼疮的动物模型）狼疮性肾炎的进展。
Zotero 插件